Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors

Results of 85 syntheses

Giorgio Biasiotto, Francesco Bertagna, Isabella Zanella, Ugo Biasiotto, Giordano Savelli, Luigi Caimi, Giovanni Bettinsoli, Raffaele Giubbini, Marco Chinol

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [90Y]DOTATOC, starting from three different radioactivity levels to treat one, two, or three patients per therapeutic session. We investigated three different starting radioactivity levels. For the low radioactivity preparation we used 5138±280 MBq of [90Y] isotope, for the medium radioactivity preparation we used 8893±900 MBq, and for the high radioactivity preparation we used 11250±715 MBq. The radiochemical purity levels for the low radioactivity preparation, medium radioactivity preparation, and high radioactivity preparation were 99.95±0.09, 99.84±0.34, and 99.84±0.53%, respectively, and the radiochemical yields of the labeling procedures were 77.52±1.28, 75.53±3.72, and 78.00±3.20%, respectively. Media fill validation of the process was performed, and the parameters of pH, bacterial endotoxins, sterility, and osmolality were tested at process control. All radiopharmaceutical preparations satisfied the predetermined specifications fixed in our protocol regardless of the starting radioactivity level. The validation of the method guaranteed the safety and quality of the final products, contributing to providing the basis for constructing an informative and successful clinical trial.

Original languageEnglish
Pages (from-to)265-270
Number of pages6
JournalNuclear Medicine Communications
Volume34
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Neuroendocrine Tumors
Quality Control
Radioactivity
Therapeutics
DOTA-Tyr(3)-90Y-octreotide
Radiopharmaceuticals
Endotoxins
Isotopes
Osmolar Concentration
Infertility
Clinical Trials
Safety

Keywords

  • [Y]DOTATOC
  • Neuroendocrine tumors
  • Quality controls
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors : Results of 85 syntheses. / Biasiotto, Giorgio; Bertagna, Francesco; Zanella, Isabella; Biasiotto, Ugo; Savelli, Giordano; Caimi, Luigi; Bettinsoli, Giovanni; Giubbini, Raffaele; Chinol, Marco.

In: Nuclear Medicine Communications, Vol. 34, No. 3, 03.2013, p. 265-270.

Research output: Contribution to journalArticle

Biasiotto, G, Bertagna, F, Zanella, I, Biasiotto, U, Savelli, G, Caimi, L, Bettinsoli, G, Giubbini, R & Chinol, M 2013, 'Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors: Results of 85 syntheses', Nuclear Medicine Communications, vol. 34, no. 3, pp. 265-270. https://doi.org/10.1097/MNM.0b013e32835ce596
Biasiotto, Giorgio ; Bertagna, Francesco ; Zanella, Isabella ; Biasiotto, Ugo ; Savelli, Giordano ; Caimi, Luigi ; Bettinsoli, Giovanni ; Giubbini, Raffaele ; Chinol, Marco. / Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors : Results of 85 syntheses. In: Nuclear Medicine Communications. 2013 ; Vol. 34, No. 3. pp. 265-270.
@article{059ad8310f154c769bd931076ab15911,
title = "Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors: Results of 85 syntheses",
abstract = "The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [90Y]DOTATOC, starting from three different radioactivity levels to treat one, two, or three patients per therapeutic session. We investigated three different starting radioactivity levels. For the low radioactivity preparation we used 5138±280 MBq of [90Y] isotope, for the medium radioactivity preparation we used 8893±900 MBq, and for the high radioactivity preparation we used 11250±715 MBq. The radiochemical purity levels for the low radioactivity preparation, medium radioactivity preparation, and high radioactivity preparation were 99.95±0.09, 99.84±0.34, and 99.84±0.53{\%}, respectively, and the radiochemical yields of the labeling procedures were 77.52±1.28, 75.53±3.72, and 78.00±3.20{\%}, respectively. Media fill validation of the process was performed, and the parameters of pH, bacterial endotoxins, sterility, and osmolality were tested at process control. All radiopharmaceutical preparations satisfied the predetermined specifications fixed in our protocol regardless of the starting radioactivity level. The validation of the method guaranteed the safety and quality of the final products, contributing to providing the basis for constructing an informative and successful clinical trial.",
keywords = "[Y]DOTATOC, Neuroendocrine tumors, Quality controls, Radiopharmaceutical",
author = "Giorgio Biasiotto and Francesco Bertagna and Isabella Zanella and Ugo Biasiotto and Giordano Savelli and Luigi Caimi and Giovanni Bettinsoli and Raffaele Giubbini and Marco Chinol",
year = "2013",
month = "3",
doi = "10.1097/MNM.0b013e32835ce596",
language = "English",
volume = "34",
pages = "265--270",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors

T2 - Results of 85 syntheses

AU - Biasiotto, Giorgio

AU - Bertagna, Francesco

AU - Zanella, Isabella

AU - Biasiotto, Ugo

AU - Savelli, Giordano

AU - Caimi, Luigi

AU - Bettinsoli, Giovanni

AU - Giubbini, Raffaele

AU - Chinol, Marco

PY - 2013/3

Y1 - 2013/3

N2 - The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [90Y]DOTATOC, starting from three different radioactivity levels to treat one, two, or three patients per therapeutic session. We investigated three different starting radioactivity levels. For the low radioactivity preparation we used 5138±280 MBq of [90Y] isotope, for the medium radioactivity preparation we used 8893±900 MBq, and for the high radioactivity preparation we used 11250±715 MBq. The radiochemical purity levels for the low radioactivity preparation, medium radioactivity preparation, and high radioactivity preparation were 99.95±0.09, 99.84±0.34, and 99.84±0.53%, respectively, and the radiochemical yields of the labeling procedures were 77.52±1.28, 75.53±3.72, and 78.00±3.20%, respectively. Media fill validation of the process was performed, and the parameters of pH, bacterial endotoxins, sterility, and osmolality were tested at process control. All radiopharmaceutical preparations satisfied the predetermined specifications fixed in our protocol regardless of the starting radioactivity level. The validation of the method guaranteed the safety and quality of the final products, contributing to providing the basis for constructing an informative and successful clinical trial.

AB - The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [90Y]DOTATOC, starting from three different radioactivity levels to treat one, two, or three patients per therapeutic session. We investigated three different starting radioactivity levels. For the low radioactivity preparation we used 5138±280 MBq of [90Y] isotope, for the medium radioactivity preparation we used 8893±900 MBq, and for the high radioactivity preparation we used 11250±715 MBq. The radiochemical purity levels for the low radioactivity preparation, medium radioactivity preparation, and high radioactivity preparation were 99.95±0.09, 99.84±0.34, and 99.84±0.53%, respectively, and the radiochemical yields of the labeling procedures were 77.52±1.28, 75.53±3.72, and 78.00±3.20%, respectively. Media fill validation of the process was performed, and the parameters of pH, bacterial endotoxins, sterility, and osmolality were tested at process control. All radiopharmaceutical preparations satisfied the predetermined specifications fixed in our protocol regardless of the starting radioactivity level. The validation of the method guaranteed the safety and quality of the final products, contributing to providing the basis for constructing an informative and successful clinical trial.

KW - [Y]DOTATOC

KW - Neuroendocrine tumors

KW - Quality controls

KW - Radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=84873410301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873410301&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e32835ce596

DO - 10.1097/MNM.0b013e32835ce596

M3 - Article

VL - 34

SP - 265

EP - 270

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 3

ER -